Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases
Cartesian Therapeutics (NASDAQ: RNAC) said it signed a strategic licensing agreement with WestGene Biopharma to develop in vivo CAR-T therapies for autoimmune diseases, combining WestGene’s targeted LNP delivery with Cartesian’s mRNA payloads from Descartes-08. A Phase 1 dose-escalation study in generalized myasthenia gravis is expected to start in 2H 2026, with data in 1H 2027. WestGene will receive an upfront payment plus potential milestones.
How this was made
The 30-second read
Why it matters
The licensing agreement creates a Phase 1 dose-escalation program in MG using Descartes-08 mRNA delivered by WestGene’s tLNPs, with expected in-human data in 1H 2027. Success could remove the ex vivo manufacturing step and enable faster expansion of multiple next-gen anti-BCMA CAR constructs and a BCMA-directed TCE into U.S. clinical development.
Market read
This is a platform/clinical-path catalyst for RNAC: a new in vivo delivery trial with defined start and data windows, plus an expansion plan across autoimmune programs.
What to watch
Key risk is whether in vivo CAR-T generation and safety/tolerability seen in WestGene’s prior work translate cleanly to Cartesian’s specific anti-BCMA constructs and MG patient population.
Background
Cartesian is a late clinical-stage autoimmune cell therapy company; Descartes-08 is in Phase 3 for generalized myasthenia gravis, and the company is extending its mRNA payloads into in vivo delivery via WestGene’s targeted LNP platform.
Ticker impact
Cartesian announced a strategic licensing deal with WestGene to run a Phase 1 in vivo CAR-T study using Descartes-08 mRNA payloads in MG, starting 2H 2026.
Near-term: modest positive bias on deal/clinical-path clarity. Medium-term: higher sensitivity to any early trial execution updates and 1H 2027 proof-of-concept signals.
This is a concrete partnership and trial initiation/expected data timing, but it does not include financial terms or interim efficacy results, limiting immediate magnitude.
Market effects
Supports the broader in vivo CAR-T delivery narrative (LNP/tLNP + mRNA payloads) and could increase investor focus on platform partnerships in autoimmune cell therapy.
Primarily US biotech sentiment; clinical execution and readouts are US-focused per the stated U.S. development intent.
Cross-border alliance highlights global competition in LNP/tLNP delivery and mRNA engineering for next-gen cell therapies.
Counterpoint
The partnership may be more about platform validation than near-term revenue; without disclosed economics, upside may be limited until trial milestones.
Key entities
- CompanyCartesian Therapeutics, Inc.
Announced the licensing agreement and will run the Phase 1 dose-escalation study using Descartes-08 mRNA payloads delivered via WestGene’s tLNPs in MG.
- CompanyWestGene Biopharma Co., Ltd.
Provides the targeted lipid nanoparticle (tLNP) delivery platform and has prior clinical experience with mRNA CAR-T constructs in oncology/autoimmune settings.
- ProgramDescartes-08
Cartesian’s mRNA payload used in the planned in vivo CAR-T Phase 1 study in generalized myasthenia gravis.
